MobiHealth News May 13, 2025
The company uses AI and ML to assist biopharma companies with clinical trials and will use the funds to expand its precision medicine and clinical development tools.
Israeli startup PhaseV, an AI-enabled clinical development company for life sciences, has secured $50 million in Series A funding in a round co-led by Accel and Insight Partners.
Existing investors Viola Ventures, LionBird and EXOR also participated in the round.
The round brings the company’s total raise to $65 million.
WHAT IT DOES
PhaseV offers biopharma sponsors and clinical research organizations (CROs) with AI- and ML-enabled insights on clinical operations, causal disease modeling, uncovering treatment response patterns in complex heterogeneity data and identifying patient subgroups for precision medicine.
“The...
Today's Sponsors
Today's Sponsor